Health AI Central
Share:
Peer-Reviewed Publication
Front Pharmacol2025;161589075.January 1, 2025Journal Article

Dexmedetomidine potently and reversibly regulates stress-mediated behaviors.

Frank D Yocca1, Dinesh K Dhull2, Subhendu Seth2, Manisha Chugh2, Sameer Sharma3, Krishnan Nandabalan3, Friso R Postma1, Michael De Vivo1
1BioXcel Therapeutics Inc., New Haven, CT, United States.
2E. Z. BioXcel Solutions Pvt. Ltd., Gurugram, Haryana, India.
3Invea Therapeutics Inc., Guilford, CT, United States.
PubMed PMC DOI PDF

Abstract

AIMS: Demonstrate that dexmedetomidine is potentially useful for treatment of psychiatric symptoms caused by acute or chronic stress by using relevant rodent models and doses predicted to achieve sufficient brain levels to activate alpha2-adrenoceptors. METHODS: In vitro characterization was performed using labeled GTPγS binding and β-arrestin recruitment. Free brain levels were measured by using…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.